Literature DB >> 12540054

Tau neurofibrillary pathology and microtubule stability.

Mary L Michaelis1, Rick T Dobrowsky, Guibin Li.   

Abstract

We previously reported that nonomolar concentrations of Taxol and several structurally diverse microtubule (MT)-stabilizing agents significantly enhanced the survival of neurons in the presence of fibrils of amyloid beta peptide (Abeta). Pretreatment of neurons with MT-stabilizing drugs also blocked Abeta-induced activation of tau hyperphosphorylation. Although tau is a substrate for several kinases, we initially focused on cdk5, as this tau kinase has been shown to be activated in Abeta-treated neurons and Alzheimer's disease (AD) brain. In an in vitro kinase assay, Taxol inhibited activation of cdk5 by Abeta. In addition, the proposed cellular cascade in which calpain activation leads to cleavage of the cdk5 regulator, p35, to the strong kinase activator p25 was also prevented. Taxol did not directly inhibit the activity of either cdk5 or calpain, indicating that other cellular components are required for the effect of the drug on Abeta activation of tau phosphorylation. Our results suggest that drugs that interact with MTs can alter signaling events in neurons, possibly because some MTs play a role in organizing protein complexes involved in responses to Abeta. Thus the cytoskeletal network may serve as a biosensor of cellular well-being.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12540054     DOI: 10.1385/JMN:19:3:289

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  21 in total

Review 1.  "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders.

Authors:  J Q Trojanowski; V M Lee
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  p25 protein in neurodegeneration.

Authors:  B C Yoo; G Lubec
Journal:  Nature       Date:  2001-06-14       Impact factor: 49.962

3.  Neurotoxicity induces cleavage of p35 to p25 by calpain.

Authors:  M S Lee; Y T Kwon; M Li; J Peng; R M Friedlander; L H Tsai
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

4.  NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein.

Authors:  M Niethammer; D S Smith; R Ayala; J Peng; J Ko; M S Lee; M Morabito; L H Tsai
Journal:  Neuron       Date:  2000-12       Impact factor: 17.173

5.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5.

Authors:  M K Ahlijanian; N X Barrezueta; R D Williams; A Jakowski; K P Kowsz; S McCarthy; T Coskran; A Carlo; P A Seymour; J E Burkhardt; R B Nelson; J D McNeish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 6.  Clearing the brain's amyloid cobwebs.

Authors:  D J Selkoe
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

7.  Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death.

Authors:  A Alvarez; R Toro; A Cáceres; R B Maccioni
Journal:  FEBS Lett       Date:  1999-10-15       Impact factor: 4.124

Review 8.  A decade of CDK5.

Authors:  R Dhavan; L H Tsai
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

9.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.

Authors:  G N Patrick; L Zukerberg; M Nikolic; S de la Monte; P Dikkes; L H Tsai
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

10.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

Authors:  M G Spillantini; J R Murrell; M Goedert; M R Farlow; A Klug; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more
  19 in total

1.  Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

Authors:  Cathy Andorfer; Christopher M Acker; Yvonne Kress; Patrick R Hof; Karen Duff; Peter Davies
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

Review 3.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 4.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

5.  CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY.

Authors:  Alexandra M Nicholson; Adriana Ferreira
Journal:  Cogn Sci (Hauppauge)       Date:  2010-07-01

6.  A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons.

Authors:  Ya-Li Zheng; Sashi Kesavapany; Maneth Gravell; Rebecca S Hamilton; Manfred Schubert; Niranjana Amin; Wayne Albers; Philip Grant; Harish C Pant
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

Review 7.  Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia.

Authors:  S Engelhardt; S Patkar; O O Ogunshola
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 8.  PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan.

Authors:  Tomohiro Kaneta
Journal:  Jpn J Radiol       Date:  2020-02-10       Impact factor: 2.374

9.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.

Authors:  Fernanda G De Felice; Diana Wu; Mary P Lambert; Sara J Fernandez; Pauline T Velasco; Pascale N Lacor; Eileen H Bigio; Jasna Jerecic; Paul J Acton; Paul J Shughrue; Elizabeth Chen-Dodson; Gene G Kinney; William L Klein
Journal:  Neurobiol Aging       Date:  2007-04-02       Impact factor: 4.673

Review 10.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.